{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:46:36Z","timestamp":1786715196586,"version":"build-2736575974"},"reference-count":115,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/1673-5374.194708","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T05:13:42Z","timestamp":1484543622000},"page":"1712","source":"Crossref","is-referenced-by-count":6,"title":["Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification"],"prefix":"10.4103","volume":"11","author":[{"given":"EdwardC","family":"Lauterbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.194708-1","doi-asserted-by":"crossref","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270-279.","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"key-10.4103\/1673-5374.194708-2","doi-asserted-by":"crossref","unstructured":"Arif M, Kato T (2009) Increased expression of PAD2 after repeated intracerebroventricular infusions of soluble Abeta(25-35) in the Alzheimer's disease model rat brain: effect of memantine. Cell Mol Biol Lett 14:703-714.","DOI":"10.2478\/s11658-009-0029-x"},{"key":"key-10.4103\/1673-5374.194708-3","doi-asserted-by":"crossref","unstructured":"Beglinger LJ, Gaydos BL, Kareken DA, Tangphao-Daniels O, Siemers ER, Mohs RC (2004) Neuropsychological test performance in healthy volunteers before and after donepezil administration. J Psychopharmacol 18:102-108.","DOI":"10.1177\/0269881104040248"},{"key":"key-10.4103\/1673-5374.194708-4","doi-asserted-by":"crossref","unstructured":"Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 68:117-122.","DOI":"10.1007\/978-3-7091-0579-5_14"},{"key":"key-10.4103\/1673-5374.194708-5","doi-asserted-by":"crossref","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson's disease. Mov Disord 30:1600-1609.","DOI":"10.1002\/mds.26431"},{"key":"key-10.4103\/1673-5374.194708-6","doi-asserted-by":"crossref","unstructured":"Cai LL, Li H, Liu JG, Liu LT, Guan J, Liu MF, Hu J, Wei Y (2011) Effects of early intervention with Huannao Yicong formula effective components on behavior and cholinergic system of \u03b2-amyloid precursor protein transgenic mice. Zhong Xi Yi Jie He Xue Bao 9:292-298.","DOI":"10.3736\/jcim20110310"},{"key":"key-10.4103\/1673-5374.194708-7","unstructured":"Cankurtaran ES, Ozalp E, Soygur H, Cakir A (2006) Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J Natl Med Assoc 98:1353-1355."},{"key":"key-10.4103\/1673-5374.194708-8","doi-asserted-by":"crossref","unstructured":"Carriere CH, Kang NH, Niles LP (2014) Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease. Neuroscience 267:114-121.","DOI":"10.1016\/j.neuroscience.2014.02.028"},{"key":"key-10.4103\/1673-5374.194708-9","doi-asserted-by":"crossref","unstructured":"Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD (2012) Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 229:208-215.","DOI":"10.1016\/j.bbr.2012.01.016"},{"key":"key-10.4103\/1673-5374.194708-10","doi-asserted-by":"crossref","unstructured":"Chiu CT, Liu G, Leeds P, Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36:2406-2421.","DOI":"10.1038\/npp.2011.128"},{"key":"key-10.4103\/1673-5374.194708-11","doi-asserted-by":"crossref","unstructured":"Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, Bok E, Jin M, Park ES, Yoon SH, Ko HW, Kim YS, Jin BK (2011) Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 60:963-974.","DOI":"10.1016\/j.neuropharm.2011.01.043"},{"key":"key-10.4103\/1673-5374.194708-12","doi-asserted-by":"crossref","unstructured":"Como PG, Rubin AJ, O'Brien CF, Lawler K, Hickey C, Rubin AE, Henderson R, McDermott MP, McDermott M, Steinberg K, Shoulson I (1997) A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov Disord 12:397-401.","DOI":"10.1002\/mds.870120319"},{"key":"key-10.4103\/1673-5374.194708-13","doi-asserted-by":"crossref","unstructured":"Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE (2006) Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 67:1268-1271.","DOI":"10.1212\/01.wnl.0000238106.10423.00"},{"key":"key-10.4103\/1673-5374.194708-14","doi-asserted-by":"crossref","unstructured":"Danivas V, Moily NS, Thimmaiah R, Muralidharan K, Purushotham M, Muthane U, Jain S (2013) Off label use of lithium in the treatment of Huntington's disease: A case series. Indian J Psychiatry 55:81-83.","DOI":"10.4103\/0019-5545.105522"},{"key":"key-10.4103\/1673-5374.194708-15","doi-asserted-by":"crossref","unstructured":"De Beaumont L, Pelleieux S, Lamarre-Th\u00e9roux L, Dea D, Poirier J; and the Alzheimer's Disease Cooperative Study (2016) Butyrylcholinesterase K and apolipoprotein E-e4 reduce the age of onset of Alzheimer's disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects. J Alzheimers Dis 54:913-922.","DOI":"10.3233\/JAD-160373"},{"key":"key-10.4103\/1673-5374.194708-16","doi-asserted-by":"crossref","unstructured":"De Marchi N, Daniele F, Ragone MA (2001) Fluoxetine in the treatment of Huntington's disease. Psychopharmacology (Berl) 153:264-266.","DOI":"10.1007\/s002130000575"},{"key":"key-10.4103\/1673-5374.194708-17","doi-asserted-by":"crossref","unstructured":"DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR Jr, Scheltens P; Alzheimer's Disease Cooperative Study Group (2007) Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 64:108-115.","DOI":"10.1001\/archneur.64.1.108"},{"key":"key-10.4103\/1673-5374.194708-18","doi-asserted-by":"crossref","unstructured":"Dong H, Yuede CM, Coughlan CA, Murphy KM, Csernansky JG (2009) Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res 1303:169-178.","DOI":"10.1016\/j.brainres.2009.09.097"},{"key":"key-10.4103\/1673-5374.194708-19","doi-asserted-by":"crossref","unstructured":"Dong H, Yuede CM, Coughlan C, Lewis B, Csernansky JG (2008) Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 33:3226-3236.","DOI":"10.1038\/npp.2008.53"},{"key":"key-10.4103\/1673-5374.194708-20","doi-asserted-by":"crossref","unstructured":"Dong H, Csernansky CA, Martin MV, Bertchume A, Vallera D, Csernansky JG (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl) 181:145-152.","DOI":"10.1007\/s00213-005-2230-6"},{"key":"key-10.4103\/1673-5374.194708-21","doi-asserted-by":"crossref","unstructured":"Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK (2009) Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72:1555-1561.","DOI":"10.1212\/01.wnl.0000344650.95823.03"},{"key":"key-10.4103\/1673-5374.194708-22","doi-asserted-by":"crossref","unstructured":"Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, Louis Tisserand G, Touchon J, Bonafe A, Ousset PJ, Ait Ameur A, Rouaud O, Ricolfi F, Vighetto A, Pasquier F, Delmaire C, Ceccaldi M, Girard N, Dufouil C, Lehericy S, et al. (2015) Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement 11:1041-1049.","DOI":"10.1016\/j.jalz.2014.10.003"},{"key":"key-10.4103\/1673-5374.194708-23","doi-asserted-by":"crossref","unstructured":"Eleuteri S, Monti B, Brignani S, Contestabile A (2009) Chronic dietary administration of valproic acid protects neurons of the rat nucleus basalis magnocellularis from ibotenic acid neurotoxicity. Neurotox Res 15:127-132.","DOI":"10.1007\/s12640-009-9013-5"},{"key":"key-10.4103\/1673-5374.194708-24","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR Jr, Weiner MW, Thomas RG, Schneider LS, Tariot PN; Alzheimer's Disease Cooperative Study (2011) Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77:1263-1271.","DOI":"10.1212\/WNL.0b013e318230a16c"},{"key":"key-10.4103\/1673-5374.194708-25","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70:191-199.","DOI":"10.1212\/01.wnl.0000287091.57376.65"},{"key":"key-10.4103\/1673-5374.194708-26","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study (2007) Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68:1588-1595.","DOI":"10.1212\/01.wnl.0000258542.58725.4c"},{"key":"key-10.4103\/1673-5374.194708-27","doi-asserted-by":"crossref","unstructured":"Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351-356.","DOI":"10.1192\/bjp.bp.110.080044"},{"key":"key-10.4103\/1673-5374.194708-28","doi-asserted-by":"crossref","unstructured":"Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106:18367-18372.","DOI":"10.1073\/pnas.0907652106"},{"key":"key-10.4103\/1673-5374.194708-29","doi-asserted-by":"crossref","unstructured":"Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 22:2081-2088.","DOI":"10.1111\/j.1460-9568.2005.04365.x"},{"key":"key-10.4103\/1673-5374.194708-30","doi-asserted-by":"crossref","unstructured":"Gulpers B, Ramakers I, Hamel R, K\u00f6hler S, Oude Voshaar R, Verhey F (2016) Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry 24:823-842.","DOI":"10.1016\/j.jagp.2016.05.015"},{"key":"key-10.4103\/1673-5374.194708-31","doi-asserted-by":"crossref","unstructured":"Hampel H, Ewers M, B\u00fcrger K, Annas P, M\u00f6rtberg A, Bogstedt A, Fr\u00f6lich L, Schr\u00f6der J, Sch\u00f6nknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, M\u00f6ller HJ, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70:922-931.","DOI":"10.4088\/JCP.08m04606"},{"key":"key-10.4103\/1673-5374.194708-32","doi-asserted-by":"crossref","unstructured":"Harrison IF, Anis HK, Dexter DT (2016) Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate. Neurosci Lett 614:16-23.","DOI":"10.1016\/j.neulet.2015.12.052"},{"key":"key-10.4103\/1673-5374.194708-33","doi-asserted-by":"crossref","unstructured":"Harrison IF, Crum WR, Vernon AC, Dexter DT (2015) Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol 172:4200-4215.","DOI":"10.1111\/bph.13208"},{"key":"key-10.4103\/1673-5374.194708-34","doi-asserted-by":"crossref","unstructured":"He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X, Li XM (2009) Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 30:1205-1216.","DOI":"10.1016\/j.neurobiolaging.2007.11.001"},{"key":"key-10.4103\/1673-5374.194708-35","doi-asserted-by":"crossref","unstructured":"Hjermind LE, Law I, J\u00f8nch A, Stokholm J, Nielsen JE (2011) Huntington's disease: effect of memantine on FDG-PET brain metabolism? J Neuropsychiatry Clin Neurosci 23:206-210.","DOI":"10.1176\/jnp.23.2.jnp206"},{"key":"key-10.4103\/1673-5374.194708-36","doi-asserted-by":"crossref","unstructured":"Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ; Members of the Alzheimer's Disease Cooperative Study (ADCS) (2008) Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29:1285-1295.","DOI":"10.1016\/j.neurobiolaging.2007.03.004"},{"key":"key-10.4103\/1673-5374.194708-37","doi-asserted-by":"crossref","unstructured":"Jeon S, Bose S, Hur J, Jun K, Kim YK, Cho KS, Koo BS (2011) A modified formulation of Chinese traditional medicine improves memory impairment and reduces A\u03b2 level in the Tg-APPswe\/PS1dE9 mouse model of Alzheimer's disease. J Ethnopharmacol 137:783-789.","DOI":"10.1016\/j.jep.2011.06.046"},{"key":"key-10.4103\/1673-5374.194708-38","doi-asserted-by":"crossref","unstructured":"Kautu BB, Carrasquilla A, Hicks ML, Caldwell KA, Caldwell GA (2013) Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling. Neurosci Lett 541:116-119.","DOI":"10.1016\/j.neulet.2013.02.026"},{"key":"key-10.4103\/1673-5374.194708-39","doi-asserted-by":"crossref","unstructured":"Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59:358-365.","DOI":"10.1016\/j.neuropharm.2010.04.008"},{"key":"key-10.4103\/1673-5374.194708-40","doi-asserted-by":"crossref","unstructured":"Kessing LV, S\u00f8nderg\u00e5rd L, Forman JL, Andersen PK (2008) Lithium treatment and risk of dementia. Arch Gen Psychiatry 65:1331-1335.","DOI":"10.1001\/archpsyc.65.11.1331"},{"key":"key-10.4103\/1673-5374.194708-41","doi-asserted-by":"crossref","unstructured":"Khan A, Jamwal S, Bijjem KR, Prakash A, Kumar P (2015) Neuroprotective effect of hemeoxygenase-1\/glycogen synthase kinase-3\u03b2 modulators in 3-nitropropionic acid-induced neurotoxicity in rats. Neuroscience 287:66-77.","DOI":"10.1016\/j.neuroscience.2014.12.018"},{"key":"key-10.4103\/1673-5374.194708-42","doi-asserted-by":"crossref","unstructured":"Kidd SK, Schneider JS (2011) Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 194:189-194.","DOI":"10.1016\/j.neuroscience.2011.08.010"},{"key":"key-10.4103\/1673-5374.194708-43","doi-asserted-by":"crossref","unstructured":"Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35:870-880.","DOI":"10.1038\/npp.2009.197"},{"key":"key-10.4103\/1673-5374.194708-44","doi-asserted-by":"crossref","unstructured":"Kim YH, Rane A, Lussier S, Andersen JK (2011) Lithium protects against oxidative stress-mediated cell death in \u03b1-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J Neurosci Res 89:1666-1675.","DOI":"10.1002\/jnr.22700"},{"key":"key-10.4103\/1673-5374.194708-45","doi-asserted-by":"crossref","unstructured":"Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, M\u00fcnch M, Barlow C, Carter T, Masliah E, Winkler J (2012) Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 35:10-19.","DOI":"10.1111\/j.1460-9568.2011.07933.x"},{"key":"key-10.4103\/1673-5374.194708-46","doi-asserted-by":"crossref","unstructured":"Kontopoulos E, Parvin JD, Feany MB (2006) \u03b1-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012-3023.","DOI":"10.1093\/hmg\/ddl243"},{"key":"key-10.4103\/1673-5374.194708-47","doi-asserted-by":"crossref","unstructured":"Lauterbach EC (2012a) Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease. Alzheimer Dis Assoc Disord 26:1-7.","DOI":"10.1097\/WAD.0b013e318214b7d0"},{"key":"key-10.4103\/1673-5374.194708-48","doi-asserted-by":"crossref","unstructured":"Lauterbach EC (2012b) Psychotropic drug effects on gene transcriptomics relevant to Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 38:107-115.","DOI":"10.1016\/j.pnpbp.2012.03.011"},{"key":"key-10.4103\/1673-5374.194708-49","doi-asserted-by":"crossref","unstructured":"Lauterbach EC (2013a) Psychotropics regulate Skp1a, Aldh1a1, and Hspa8 transcription-\u201dpotential to delay Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 40:236-239.","DOI":"10.1016\/j.pnpbp.2012.08.021"},{"key":"key-10.4103\/1673-5374.194708-50","doi-asserted-by":"crossref","unstructured":"Lauterbach EC (2013b) Neuroprotective effects of psychotropic drugs in Huntington's disease. Int J Mol Sci 14:22558-22603.","DOI":"10.3390\/ijms141122558"},{"key":"key-10.4103\/1673-5374.194708-51","unstructured":"Lauterbach EC (2016) Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurogener Dis 5:29-51."},{"key":"key-10.4103\/1673-5374.194708-52","doi-asserted-by":"crossref","unstructured":"Lauterbach EC, Mendez MF (2011) Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research. J Neuropsychiatry Clin Neurosci 23:242-260.","DOI":"10.1176\/jnp.23.3.jnp242"},{"key":"key-10.4103\/1673-5374.194708-53","doi-asserted-by":"crossref","unstructured":"Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF (2010) Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 22:8-18.","DOI":"10.1176\/jnp.2010.22.1.8"},{"key":"key-10.4103\/1673-5374.194708-54","doi-asserted-by":"crossref","unstructured":"Lee ST, Chu K, Park JE, Kang L, Ko SY, Jung KH, Kim M (2006) Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res 1118:199-207.","DOI":"10.1016\/j.brainres.2006.08.035"},{"key":"key-10.4103\/1673-5374.194708-55","doi-asserted-by":"crossref","unstructured":"Leonard DP, Kidson MA, Brown JG, Shannon PJ, Taryan S (1975) A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry 9:115-118.","DOI":"10.3109\/00048677509159834"},{"key":"key-10.4103\/1673-5374.194708-56","doi-asserted-by":"crossref","unstructured":"Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP (2013) Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int J Neurosci 123:73-79.","DOI":"10.3109\/00207454.2012.729234"},{"key":"key-10.4103\/1673-5374.194708-57","doi-asserted-by":"crossref","unstructured":"Lieu CA, Dewey CM, Chinta SJ, Rane A, Rajagopalan S, Batir S, Kim YH, Andersen JK (2014) Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res 1591:111-117.","DOI":"10.1016\/j.brainres.2014.10.032"},{"key":"key-10.4103\/1673-5374.194708-58","doi-asserted-by":"crossref","unstructured":"Loewenstein DA, Curiel RE, Greig MT, Bauer RM, Rosado M, Bowers D, Wicklund M, Crocco E, Pontecorvo M, Joshi AD, Rodriguez R, Barker WW, Hidalgo J, Duara R (2016) A novel cognitive stress test for the detection of preclinical Alzheimer disease: discriminative properties and relation to amyloid load. Am J Geriatr Psychiatry 24:804-813.","DOI":"10.1016\/j.jagp.2016.02.056"},{"key":"key-10.4103\/1673-5374.194708-59","doi-asserted-by":"crossref","unstructured":"Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72:2115-2121.","DOI":"10.1212\/WNL.0b013e3181aa52d3"},{"key":"key-10.4103\/1673-5374.194708-60","doi-asserted-by":"crossref","unstructured":"Luo G, Liu M, He J, Guo H, Xue M, Wang X, Li XM (2014) Quetiapine attenuates recognition memory impairment and hippocampal oxidative stress in a transgenic mouse model of Alzheimer's disease. Neuroreport 25:647-650.","DOI":"10.1097\/WNR.0000000000000150"},{"key":"key-10.4103\/1673-5374.194708-61","doi-asserted-by":"crossref","unstructured":"Mahlknecht P, Seppi K, Poewe W (2015) The concept of prodromal Parkinson's disease. J Parkinson's Dis 5:681-697.","DOI":"10.3233\/JPD-150685"},{"key":"key-10.4103\/1673-5374.194708-62","doi-asserted-by":"crossref","unstructured":"Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM (2010) Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176:870-880.","DOI":"10.2353\/ajpath.2010.090452"},{"key":"key-10.4103\/1673-5374.194708-63","doi-asserted-by":"crossref","unstructured":"McBride SM, Choi CH, Schoenfeld BP, Bell AJ, Liebelt DA, Ferreiro D, Choi RJ, Hinchey P, Kollaros M, Terlizzi AM, Ferrick NJ, Koenigsberg E, Rudominer RL, Sumida A, Chiorean S, Siwicki KK, Nguyen HT, Fortini ME, McDonald TV, Jongens TA (2010) Pharmacological and genetic reversal of age-dependent cognitive deficits attributable to decreased presenilin function. J Neurosci 30:9510-9522.","DOI":"10.1523\/JNEUROSCI.1017-10.2010"},{"key":"key-10.4103\/1673-5374.194708-64","doi-asserted-by":"crossref","unstructured":"Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A (2010) Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 17:130-141.","DOI":"10.1007\/s12640-009-9090-5"},{"key":"key-10.4103\/1673-5374.194708-65","doi-asserted-by":"crossref","unstructured":"Morris G, Berk M (2016) The putative use of lithium in Alzheimer's disease. Curr Alzheimer Res 13:853-861.","DOI":"10.2174\/1567205013666160219113112"},{"key":"key-10.4103\/1673-5374.194708-66","doi-asserted-by":"crossref","unstructured":"Motoi Y, Shimada K, Ishiguro K, Hattori N (2014) Lithium and autophagy. ACS Chem Neurosci 5:434-442.","DOI":"10.1021\/cn500056q"},{"key":"key-10.4103\/1673-5374.194708-67","doi-asserted-by":"crossref","unstructured":"Mowla A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27:67-70.","DOI":"10.1097\/JCP.0b013e31802e0002"},{"key":"key-10.4103\/1673-5374.194708-68","doi-asserted-by":"crossref","unstructured":"Nakamura S, Murayama N, Noshita T, Katsuragi R, Ohno T (2006) Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Eur J Pharmacol 548:115-122.","DOI":"10.1016\/j.ejphar.2006.07.049"},{"key":"key-10.4103\/1673-5374.194708-69","doi-asserted-by":"crossref","unstructured":"Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102:6990-6995.","DOI":"10.1073\/pnas.0500466102"},{"key":"key-10.4103\/1673-5374.194708-70","doi-asserted-by":"crossref","unstructured":"Noh H, Seo H (2014) Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience 266:255-265.","DOI":"10.1016\/j.neuroscience.2014.02.012"},{"key":"key-10.4103\/1673-5374.194708-71","doi-asserted-by":"crossref","unstructured":"Nunes MA, Sch\u00f6we NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SI, Balthazar J, Albuquerque MS, Caetano AL, Viel TA, Buck HS (2015) Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease. PLoS One 10:e0142267.","DOI":"10.1371\/journal.pone.0142267"},{"key":"key-10.4103\/1673-5374.194708-72","unstructured":"Nunes MA, Viel TA, Buck HS (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10:104-107."},{"key":"key-10.4103\/1673-5374.194708-73","doi-asserted-by":"crossref","unstructured":"Nunes PV, Forlenza OV, Gattaz WF (2007) Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190:359-360.","DOI":"10.1192\/bjp.bp.106.029868"},{"key":"key-10.4103\/1673-5374.194708-74","doi-asserted-by":"crossref","unstructured":"Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG (2011) The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-\u00df42 with memantine. Behav Brain Res 221:594-603.","DOI":"10.1016\/j.bbr.2010.05.033"},{"key":"key-10.4103\/1673-5374.194708-75","doi-asserted-by":"crossref","unstructured":"Obermayr RP, Mayerhofer L, Knechtelsdorfer M, Mersich N, Huber ER, Geyer G, Tragl KH (2005) The age-related down-regulation of the growth hormone\/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Exp Gerontol 40:157-163.","DOI":"10.1016\/j.exger.2004.11.001"},{"key":"key-10.4103\/1673-5374.194708-76","doi-asserted-by":"crossref","unstructured":"Ondo WG, Mejia NI, Hunter CB (2007) A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 13:453-454.","DOI":"10.1016\/j.parkreldis.2006.08.005"},{"key":"key-10.4103\/1673-5374.194708-77","doi-asserted-by":"crossref","unstructured":"Peters O, Lorenz D, Fesche A, Schmidtke K, H\u00fcll M, Perneczky R, R\u00fcther E, M\u00f6ller HJ, Jessen F, Maier W, Kornhuber J, Jahn H, Luckhaus C, Gertz HJ, Schr\u00f6der J, Pantel J, Teipel S, Wellek S, Fr\u00f6lich L, Heuser I (2012) A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 16:544-548.","DOI":"10.1007\/s12603-012-0062-8"},{"key":"key-10.4103\/1673-5374.194708-78","doi-asserted-by":"crossref","unstructured":"Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379-2388.","DOI":"10.1056\/NEJMoa050151"},{"key":"key-10.4103\/1673-5374.194708-79","unstructured":"Piersanti M, Capannolo M, Turchetti M, Serroni N, De Berardis D, Evangelista P, Costantini P, Orsini A, Rossi A, Maggio R (2014) Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy. Riv Psichiatr 49:34-40."},{"key":"key-10.4103\/1673-5374.194708-80","doi-asserted-by":"crossref","unstructured":"Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, N\u00e9ri C, Hayden MR (2012) NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 48:282-289.","DOI":"10.1016\/j.nbd.2012.06.026"},{"key":"key-10.4103\/1673-5374.194708-81","doi-asserted-by":"crossref","unstructured":"Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W, Wang K, Song W (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205:2781-2789.","DOI":"10.1084\/jem.20081588"},{"key":"key-10.4103\/1673-5374.194708-82","doi-asserted-by":"crossref","unstructured":"Reilmann R, Leavitt BR, Ross CA (2014) Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 29:1335-1341.","DOI":"10.1002\/mds.26011"},{"key":"key-10.4103\/1673-5374.194708-83","doi-asserted-by":"crossref","unstructured":"Salloway S, Correia S, Richardson S (2008) Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI. Int Psychogeriatr 20:40-46.","DOI":"10.1017\/S1041610207005650"},{"key":"key-10.4103\/1673-5374.194708-84","doi-asserted-by":"crossref","unstructured":"Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group (2004) Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63:651-657.","DOI":"10.1212\/01.WNL.0000134664.80320.92"},{"key":"key-10.4103\/1673-5374.194708-85","doi-asserted-by":"crossref","unstructured":"Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17:170-178.","DOI":"10.1093\/hmg\/ddm294"},{"key":"key-10.4103\/1673-5374.194708-86","doi-asserted-by":"crossref","unstructured":"Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943.","DOI":"10.1001\/jama.294.15.1934"},{"key":"key-10.4103\/1673-5374.194708-87","doi-asserted-by":"crossref","unstructured":"Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, Banerjee P, Wisniewski T (2008) Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86:2784-2791.","DOI":"10.1002\/jnr.21713"},{"key":"key-10.4103\/1673-5374.194708-88","doi-asserted-by":"crossref","unstructured":"Schuff N, Suhy J, Goldman R, Xu Y, Sun Y, Truran-Sacrey D, Murthy A (2011) An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging 32:2318.e31-41.","DOI":"10.1016\/j.neurobiolaging.2010.04.005"},{"key":"key-10.4103\/1673-5374.194708-89","doi-asserted-by":"crossref","unstructured":"Shi J, Tian J, Zhang X, Zeng C, Wei M, Wang P, Wang Y (2013) A combination extract of Renshen (Panax Ginseng), Yinyanghuo (Herba Epimedii Brevicornus), Yuanzhi (Radix Palygalae) and Jianghuang (Rhizoma Curcumae Longae) decreases glycogen synthase kinase 3beta expression in brain cortex of APPV7171 transgenic mice. J Tradit Chin Med 33:211-217.","DOI":"10.1016\/S0254-6272(13)60127-2"},{"key":"key-10.4103\/1673-5374.194708-90","doi-asserted-by":"crossref","unstructured":"Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, Allen MJ, Hardy J, Lovestone S, Partridge L (2010) Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 6:e1001087.","DOI":"10.1371\/journal.pgen.1001087"},{"key":"key-10.4103\/1673-5374.194708-91","doi-asserted-by":"crossref","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 7:280-292.","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"key-10.4103\/1673-5374.194708-92","doi-asserted-by":"crossref","unstructured":"Stip E, Dufresne J, Lussier I, Yatham L (2000) A double-blind, placebo-controlled study of the effects of lithium on cognition in healthy subjects: mild and selective effects on learning. J Affect Disord 60:147-157.","DOI":"10.1016\/S0165-0327(99)00178-0"},{"key":"key-10.4103\/1673-5374.194708-93","doi-asserted-by":"crossref","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 68:853-861.","DOI":"10.1001\/archgenpsychiatry.2011.72"},{"key":"key-10.4103\/1673-5374.194708-94","doi-asserted-by":"crossref","unstructured":"Tariot PN, Aisen PS (2009) Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 70:919-921.","DOI":"10.4088\/JCP.09com05331"},{"key":"key-10.4103\/1673-5374.194708-95","doi-asserted-by":"crossref","unstructured":"Tempier A, He J, Zhu S, Zhang R, Kong L, Tan Q, Luo H, Kong J, Li XM (2013) Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. Curr Alzheimer Res 10:199-206.","DOI":"10.2174\/1567205011310020010"},{"key":"key-10.4103\/1673-5374.194708-96","doi-asserted-by":"crossref","unstructured":"Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N (2006) Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30:1125-1128.","DOI":"10.1016\/j.pnpbp.2006.04.020"},{"key":"key-10.4103\/1673-5374.194708-97","doi-asserted-by":"crossref","unstructured":"Trujillo-Estrada L, Jimenez S, De Castro V, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, Navarro V, Sanchez-Varo R, Sanchez-Mejias E, Davila JC, Vizuete M, Gutierrez A, Vitorica J (2013) In vivo modification of Abeta plaque toxicity as a novel neuroprotective lithium-mediated therapy for Alzheimer's disease pathology. Acta Neuropathol Commun 1:73.","DOI":"10.1186\/2051-5960-1-73"},{"key":"key-10.4103\/1673-5374.194708-98","doi-asserted-by":"crossref","unstructured":"Van Dam D, Coen K, De Deyn PP (2008) Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology (Berl) 197:37-43.","DOI":"10.1007\/s00213-007-1010-x"},{"key":"key-10.4103\/1673-5374.194708-99","doi-asserted-by":"crossref","unstructured":"Van Dam D, De Deyn PP (2006) Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16:59-69.","DOI":"10.1016\/j.euroneuro.2005.06.005"},{"key":"key-10.4103\/1673-5374.194708-100","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Baastrup PC, Petersson H (1977) Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 56:183-188.","DOI":"10.1111\/j.1600-0447.1977.tb03561.x"},{"key":"key-10.4103\/1673-5374.194708-101","doi-asserted-by":"crossref","unstructured":"Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC (2007) Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One 2:e504.","DOI":"10.1371\/journal.pone.0000504"},{"key":"key-10.4103\/1673-5374.194708-102","doi-asserted-by":"crossref","unstructured":"Wang J, Zhang Y, Xu H, Zhu S, Wang H, He J, Zhang H, Guo H, Kong J, Huang Q, Li XM (2014) Fluoxetine improves behavioral performance by suppressing the production of soluble \u03b2-amyloid in APP\/PS1 mice. Curr Alzheimer Res 11:672-680.","DOI":"10.2174\/1567205011666140812114715"},{"key":"key-10.4103\/1673-5374.194708-103","doi-asserted-by":"crossref","unstructured":"Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106:603-612.","DOI":"10.1016\/S0306-4522(01)00311-6"},{"key":"key-10.4103\/1673-5374.194708-104","doi-asserted-by":"crossref","unstructured":"Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, Mamikonyan E, Kales HC (2016) Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 73:535-541.","DOI":"10.1001\/jamaneurol.2016.0031"},{"key":"key-10.4103\/1673-5374.194708-105","doi-asserted-by":"crossref","unstructured":"Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 61:375-383.","DOI":"10.1016\/S0361-9230(03)00141-2"},{"key":"key-10.4103\/1673-5374.194708-106","doi-asserted-by":"crossref","unstructured":"Wu CR, Lin HC, Su MH (2014) Reversal by aqueous extracts of Cistanche tubulosa from behavioral deficits in Alzheimer's disease-like rat model: relevance for amyloid deposition and central neurotransmitter function. BMC Complement Altern Med 14:202.","DOI":"10.1186\/1472-6882-14-202"},{"key":"key-10.4103\/1673-5374.194708-107","doi-asserted-by":"crossref","unstructured":"Wu YY, Wang X, Tan L, Liu D, Liu XH, Wang Q, Wang JZ, Zhu LQ (2013) Lithium attenuates scopolamine-induced memory deficits with inhibition of GSK-3\u03b2 and preservation of postsynaptic components. J Alzheimers Dis 37:515-527.","DOI":"10.3233\/JAD-130521"},{"key":"key-10.4103\/1673-5374.194708-108","doi-asserted-by":"crossref","unstructured":"Ximenes JC, Neves KR, Leal LK, do Carmo MR, Brito GA, Naffah-Mazzacoratti Mda G, Cavalheiro \u00c9A, Viana GS (2015) Valproic acid neuroprotection in the 6-OHDA model of Parkinson's disease is possibly related to its anti-inflammatory and HDAC inhibitory properties. J Neurodegener Dis 2015:313702.","DOI":"10.1155\/2015\/313702"},{"key":"key-10.4103\/1673-5374.194708-109","doi-asserted-by":"crossref","unstructured":"Yong Y, Ding H, Fan Z, Luo J, Ke ZJ (2011) Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease. Neurochem Res 36:367-374.","DOI":"10.1007\/s11064-010-0368-z"},{"key":"key-10.4103\/1673-5374.194708-110","doi-asserted-by":"crossref","unstructured":"Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46:1130-1140.","DOI":"10.1016\/j.neuropharm.2004.02.005"},{"key":"key-10.4103\/1673-5374.194708-111","doi-asserted-by":"crossref","unstructured":"Z\u00e1dori D, Geisz A, V\u00e1mos E, V\u00e9csei L, Kliv\u00e9nyi P (2009) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 94:148-153.","DOI":"10.1016\/j.pbb.2009.08.001"},{"key":"key-10.4103\/1673-5374.194708-112","doi-asserted-by":"crossref","unstructured":"Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-\u00df\u00df production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24:739-749.","DOI":"10.3233\/JAD-2011-101875"},{"key":"key-10.4103\/1673-5374.194708-113","unstructured":"Zhu S, Shi R, Li V, Wang J, Zhang R, Tempier A, He J, Kong J, Wang JF, Li XM (2014) Quetiapine attenuates glial activation and proinflammatory cytokines in APP\/PS1 transgenic mice via inhibition of nuclear factor-\u03baB pathway. Int J Neuropsychopharmacol 18:pii:pyu022."},{"key":"key-10.4103\/1673-5374.194708-114","doi-asserted-by":"crossref","unstructured":"Zhu S, He J, Zhang R, Kong L, Tempier A, Kong J, Li XM (2013) Therapeutic effects of quetiapine on memory deficit and brain \u03b2-amyloid plaque pathology in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 10:270-278.","DOI":"10.2174\/1567205011310030006"},{"key":"key-10.4103\/1673-5374.194708-115","doi-asserted-by":"crossref","unstructured":"Zimmer ER, Kalinine E, Haas CB, Torrez VR, Souza DO, Muller AP, Portela LV (2012) Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats. Curr Alzheimer Res 9:1182-1190.","DOI":"10.2174\/156720512804142877"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:26:06Z","timestamp":1786713966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.194708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":115,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"alternative-id":["194708"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.194708","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}